TIDM57MC
RNS Number : 1116M
Wellcome Trust Finance plc
10 January 2023
Wellcome Trust Finance plc
Annual Report and Financial Statements
Wellcome Trust and Wellcome Trust Finance plc (a wholly owned
subsidiary of The Wellcome Trust Limited as trustee of the Wellcome
Trust) announce that they have each published their Annual Report
and Financial Statements for the year to 30 September 2022 today. A
copy of each document is available on the Wellcome Trust website
.
Wellcome Trust has today issued the following press release in
connection with the publication of its Annual Report and Financial
Statements:
We are pleased to report that our charitable expenditure on
Wellcome's mission to support science to solve the urgent health
challenges facing everyone was GBP1.4 billion, an increase of 11%
from 2020/21. Our investment base fell slightly to GBP37.8 billion,
a total return of 1.7 per cent, or -5.9 per cent after inflation,
for the year to 30 September 2022.
The portfolio was resilient in a much more difficult year as
financial markets faced multiple headwinds. After a long period of
strong returns, the endowment remains very healthy and will
continue to provide the resources for our commitment to spend
GBP16bn on supporting science to solve urgent health challenges
over the coming decade. We have returned 275 per cent cumulative
(14.1 per cent annualised) in the decade since September 2012,
recording positive returns in each of these years. Returns have
been 819 per cent cumulative (11.7 per cent annualised) over 20
years. Since the inception of our investment portfolio in 1985, it
has provided a total return averaging 13.8 per cent a year.
We maintain a AAA/Aaa (stable) credit rating. Leverage stood at
7.1 per cent ([1]) on 30(th) September. We issued no new bonds
during the year. We have no impending bond expiries until 2027.
Given our long-term investment performance, we remain committed
to spending GBP16 billion on our charitable activities over the
next ten years. This compares to around GBP5 billion over the last
five years. While higher inflation will mean that our money can't
fund as much work as it otherwise would have done, t his funding
will increase our commitments to combat the three key worldwide
health challenges of mental health, infectious disease and climate
and health as well as maintaining high levels of support for
discovery research.
We saw mixed returns across the asset classes in which we invest
(public equity, private equity, venture capital, hedge funds and
property). Public equities and equity long short hedge funds
delivered sharply negative returns while all other assets classes
delivered positive returns, helped by a major tailwind from
sterling weakness. As Sterling weakened, it moved further below
long-term fundamental fair value leading us to increase currency
hedges. At the end of the financial year, Sterling exposure stood
at 23.9 per cent. We have maintained higher than usual levels of
cash because of the difficult environment. On 30(th) September, our
cash position was 8.2 per cent of gross assets.
Our strategy to achieve a net zero portfolio by 2050 at the
latest was published in July 2021. Our annual report includes the
second update on our net zero tracking data, which shows a positive
trajectory. The target and strategy are and will continue to be an
integral part of our investment decision-making and engagement.
[1] Leverage is an Alternative Performance Measure, defined and
reconciled in Note 15(g) of the Wellcome Trust Annual Report and
Financial Statements for the year to 30 September 2022
Julia Gillard, Chair of the Wellcome Trust, said: " "
"A strong year for Wellcome saw us funding across a broader
range of disciplines and with more money behind curiosity-driven
science than ever before in our discovery research programme. We've
also funded exciting research and initiatives in climate and
health, mental health and infectious disease. We are developing
plans for advocacy campaigns that complement our funding by pushing
for actions that will have a positive impact on research and, most
importantly, on people's health. We're entering the new year
confident that through our funding and campaigning we will make an
even bigger impact.
"Our investment team have had to work hard this year to protect
the endowment. However, their careful stewardship and long-term
thinking over many years has put us in a strong position today. The
exceptional long-term performance of the investment portfolio has
meant that despite the tough economic environment, we can stick to
our high level of spending commitments and keep supporting science
to solve urgent health challenges.'
Nick Moakes, Chief Investment Officer at Wellcome, added: "The
portfolio has had a tough year against a difficult market backdrop.
Our returns were the weakest returns since the Global Financial
Crisis and, although positive in nominal Sterling terms, inflation
has eroded the real value of our assets. We have been expecting a
more difficult world for some time following more than a decade of
extraordinary monetary and fiscal support. We do not expect things
to get any easier in the near term. Our primary focus is therefore
to protect long-term value as much as possible while maintaining
ample liquidity to fund the mission. We will also look to take
advantage of any exceptional opportunities that emerge from the
current volatility to underpin future returns. The best investments
are often made in the most difficult times."
Wellcome Trust Finance plc further announces that a copy of its
Annual Report and Financial Statements for the year ended 30
September 2022 has been submitted to the National Storage Mechanism
and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
In accordance with the Disclosure and Transparency Rules, the
following information is taken from the Annual Report and Financial
Statements for Wellcome Trust Finance plc for the year ended 30
September 2022:
Wellcome Trust Finance plc
Annual Report and Financial Statements
Year ended 30 September 2022
Strategic Report
The directors of Wellcome Trust Finance plc (the "Company" and
the "Directors") present their strategic report for the year ended
30 September 2022 (the "Strategic Report").
Strategy and objectives
The principal activity of the Company is to meet its obligations
relating to the bonds that it has previously issued and admitted to
trading on the London Stock Exchange and to continue to lend the
proceeds to other group entities.
Review of the business and future developments
The Company has one tranche of bonds outstanding: GBP550 million
issued on 25 July 2006 of 4.625% Guaranteed Bonds due July 2036.
The Company continues to receive interest on loans to the Wellcome
Trust and to pay interest on the July 2036 Bond liabilities. The
Company has not issued any bonds during the year and does not
expect to issue any bonds in the foreseeable future. Income of
GBP29,072,237 (2021: GBP38,067,314) and cost of sales of
GBP25,772,755 (2021: GBP34,666,669) are lower than prior year
comparatives. The reduction in income relates to the repayment of
one of the loans with Wellcome Trust in the prior year and the
reduction in cost of sales is due to the May 2021 Bond liabilities
which matured in the prior year.
The Bonds are admitted to trading on the London Stock Exchange.
The obligations of the Company in relation to the Bonds are
governed by Trust Deeds between the Company, The Wellcome Trust
Limited, as trustee of the Wellcome Trust, and Citicorp Trustee
Company Limited, as the trustee for the holders of the Bonds. The
payment of all amounts due in respect of the Bonds is
unconditionally and irrevocably guaranteed pursuant to the terms of
a guarantee given by The Wellcome Trust Limited, as corporate
trustee of the Wellcome Trust; the guarantee is part of the Trust
Deeds.
The Company loaned the proceeds from the Bonds to Wellcome Trust
group (the "Group") undertakings and receives interest on these
loans.
Results for the year
The Company made a profit of GBP3,251,574 (2021: GBP3,415,927 )
during the year ended 30 September 2022. As at 30 September 2022
the Company had net assets of GBP137,500,000 (2021: GBP137,500,000)
and cash of GBP1,146 (2021: GBPnil).
Key performance indicators
Due to the nature of the Company's operations, the key
performance measures are that the Company meets all its legal
obligations to the Bond holders and that the Company achieves
sufficient return on its assets to be profitable before any
donations to the Wellcome Trust as Gift Aid. During the year the
Company met all its legal obligations to the Bond holders and made
a net profit before donations to Wellcome Trust as Gift Aid.
Financial risk management objectives and policies
The Directors of the Company implement policies to manage the
inherent risks relating to the financial assets and liabilities of
the Company.
The Directors have assessed for each financial asset and
liability: the market risk, currency risk, interest rate risk,
liquidity risk, and credit risk exposure. The Company is not
exposed to significant market risk or interest rate risk because
the Company's main financial assets have fixed redemption values,
fixed interest rates and fixed maturity dates, which match those of
its financial liabilities. The currency risk exposure is limited to
the payment of one administrative expense amount per annum. The
liquidity risk of the Company is mitigated by the matching of the
cash flows from the Company's financial assets and liabilities.
Credit risk exposure of the Company's loans is reduced by the
Company only advancing loans to entities within the Group. Credit
risk exposure of the Company's remaining financial assets is
reduced by stringent selection procedures for any external
counterparties with which the Company transacts. The directors have
assessed the impact of the events in Russia and Ukraine and do not
believe it materially impacts the operations of the Company, or its
ability
to continue to operate for the foreseeable future, being at
least 12 months from the date of signing the Financial
Statements.
Financial risk management objectives and policies
The Company's internal control and risk management, which
includes consideration of the impact of Covid-19 and climate change
are considered at a group level and documented within the Wellcome
Trust Annual Report and Financial Statements 2022 which are
available from Wellcome's website at (
wellcome.org/news-and-reports/reports ) .
The Company's internal control and risk management is undertaken
as part of the Wellcome Trust's processes, which are detailed in
the Wellcome Trust Annual Report and Financial Statements,
available at wellcome.org/news-and-reports/reports . The key
elements of this specifically applicable to the Company are:
-- delegation: there is a clear organisational structure with
documented lines of authority and responsibility for control and
documented procedures for reporting decisions, actions and issues;
and
-- review: the Group Audit and Risk Committee reviews the
effectiveness of the Company's internal control, its financial
reporting process, the independence of its statutory auditors and
its compliance with relevant statutory and finance regulations and
advises the Directors of the Company of any relevant matters.
Section 172 statement
The Board of Directors, in line with their duties under s172 of
the Companies Act 2006, act in a way they consider, in good faith,
would be most likely to promote the success of the Company for the
benefit of its members as a whole, and in doing so have regard to a
range of matters when making decisions for the long term.
The key stakeholders of the Company are considered to be
Wellcome Trust (as the sole member), the other Wellcome Trust Group
entities and the holders of the Bonds. We ensure that the
requirements of s172(1) Companies Act 2006 are met and the
interests of our stakeholder groups are considered through a
combination of the following:
-- The Board sets the Company's purpose and strategy which
considers the long-term sustainable success of the Company and our
impact on key stakeholders. The key purpose is discussed under Key
performance indicators above.
-- The Board's risks management procedures identify the
principal risks facing the Company, and the mitigations in place to
manage the impact of these risks. This is discussed under Financial
risk management objectives and policies above.
-- The Company has no employees and no carbon generating assets.
The Wellcome Trust group's consideration of Social Responsibility,
including Climate change and energy transition is discussed in
their Annual Report and Financial Statements.
Corporate and social responsibility
Due to the nature of its activities the Company has a minimal
environmental impact. The Group's approach to social responsibility
is detailed in the Wellcome Trust Annual Report and Financial
Statements, which are available at
wellcome.org/news-and-reports/reports
This report was approved by the Board of Directors and signed on
9 January 2023 on its behalf by:
Karen Chadwick
Director
9 January 2023
Directors' Report
The Directors of Wellcome Trust Finance plc p resent their
report and the audited Financial Statements for the year ended 30
September 2022.
Future developments
These are discussed in the Strategic Report.
Going Concern and Viability
The Directors have a reasonable expectation that the Company has
adequate resources to continue in operational existence and to meet
any commitments as they fall due for the foreseeable future, being
at least 12 months from the date of signing the Financial
Statements. The maturities of the loans to Parent undertakings will
match the maturity of the July 2036 Bond liabilities, which will
allow the Bonds to be repaid to investors on maturity. The interest
from the loans with Wellcome Trust is sufficient to meet the fixed
rate interest payment to bond holders. Accordingly, they continue
to adopt the going concern basis in preparing the Financial
Statements. The Directors have considered the impact of Covid-19
and the impact of Russia and Ukraine on the Company and have
concluded there are no material uncertainties related to these
events or conditions that may cast doubt upon the Company's ability
to continue as a going concern.
Employees
There are no employees of the Company (2021: nil).
The administration of the Company is undertaken by staff from
the Wellcome Trust. The Wellcome Trust has not incurred any
incremental staff costs due to the administration of this
Company.
Dividends
The Directors do not propose the payment of a dividend (2021:
GBPnil). The Company has a policy to donate its taxable profits as
Gift Aid to the Wellcome Trust.
Financial risk management objectives and policies
These are discussed in the Strategic Report.
Corporate Governance
The Company is limited by shares. Its governing documents are
its articles of association. The shareholder of the Company is The
Wellcome Trust Limited, as trustee of the Wellcome Trust. The
Company is a wholly owned subsidiary of the Wellcome Trust through
its corporate trustee, The Wellcome Trust Limited. The Company is
not subject to the requirements of the UK Corporate Governance
Code. The governance policies of the Group and of the Wellcome
Trust are included in the Wellcome Trust's Annual Report and
Financial Statements for the year ended 30 September 2022.
The Group Audit and Risk Committee, the Investment Committee and
the internal audit function of the Wellcome Trust oversee all group
entities. The Company complies with all applicable filing and
information requirements of the Financial Conduct Authority.
Directors and their interests
The Directors of the Company who were in office during the year
and up to the date of signing the Financial Statements were:
Karen Chadwick
Nicholas Moakes
Peter Pereira Gray (resigned on 30 September 2022)
Fabian Thehos
None of the Directors held any beneficial interest in the shares
of the Company or any interest in its Parent undertaking the
Wellcome Trust through its corporate trustee, The Wellcome Trust
Limited.
Each of the Directors is an employee of the Group and receives
remuneration from the Group as an employee. No remuneration is paid
to any Director for their services as a Director.
Directors' indemnity policy
The Company is party to a Group-wide directors' and officers'
liability insurance policy which provides cover to all the current
Directors. There are no qualifying indemnity provisions (as defined
in the Companies Act 2006) that benefit the Directors of the
Company.
Statement of disclosure of information to auditor
Each Director in office at the date of approving this report
confirms that:
-- so far as the Director is aware, there is no relevant audit
information of which the Company's auditor is unaware; and
-- each Director has taken all the steps that ought to have been
taken as a Director in order to make themselves aware of any
relevant audit information and to establish that the Company's
auditors is aware of that information.
Independent auditors
In accordance with Section 485 of the Companies Act 2006, a
resolution dated 9 January 2023 was passed by the members
re-appointing Deloitte LLP as auditors of the Company.
Events after the end of the reporting period
There have been no subsequent events requiring disclosure.
This report was approved by the Board of Directors and signed on
its behalf on 9 January 2023 by:
Karen Chadwick
Director
Statement of Directors' Responsibilities
The Directors are responsible for preparing the Strategic
Report, Directors' Report and the Financial Statements in
accordance with applicable law and regulations.
Company law requires the Directors to prepare Financial
Statements for each financial year. Under that law the Directors
have prepared the Financial Statements in accordance with United
Kingdom Generally Accepted Accounting Practice (United Kingdom
Accounting Standards and applicable law), including FRS 102 the
Financial Reporting Standards applicable in U.K. and Republic of
Ireland. Under company law the Directors must not approve the
Financial Statements unless they are satisfied that they give a
true and fair view of the state of affairs of the Company and of
the profit or loss of the Company for that period. In preparing
these Financial Statements, the Directors are required to:
-- select suitable accounting policies and then apply them consistently;
-- make judgements and accounting estimates that are reasonable and prudent;
-- state whether applicable UK Accounting Standards have been
followed, subject to any material departures disclosed and
explained in the Financial Statements; and
-- prepare the Financial Statements on the going concern basis
unless it is inappropriate to presume that the Company will
continue in business.
The Directors are responsible for keeping adequate accounting
records that are sufficient to show and explain the Company's
transactions and disclose with reasonable accuracy at any time the
financial position of the Company and enable them to ensure that
the Financial Statements comply with the Companies Act 2006. They
are also responsible for safeguarding the assets of the Company and
hence for taking reasonable steps for the prevention and detection
of fraud and other irregularities.
The Directors are responsible for the maintenance and integrity
of the corporate and financial information included on its Parent
undertaking's (Wellcome Trust's) website. Legislation in the United
Kingdom governing the preparation and dissemination of Financial
Statements may differ from legislation in other jurisdictions.
The Directors consider that the Annual Report and Financial
Statements, taken as a whole, is fair, balanced and understandable
and provides the information necessary for shareholders to assess
the Company's performance, business model and strategy.
Each of the Directors, whose names are listed in the Directors'
Report confirm that, to the best of their knowledge:
-- the Financial Statements, which have been prepared in
accordance with United Kingdom Generally Accepted Accounting
Practice (United Kingdom Accounting Standards and applicable law),
including FRS 102 the Financial Reporting Standards applicable in
U.K. and Republic of Ireland, give a true and fair view of the
assets, liabilities, financial position and result of the Company;
and
-- the Directors' Report contained in this section of the Annual
Report includes a fair review of the development and performance of
the business and the position of the Company, together with a
description of the principal risks and uncertainties that it
faces.
INDEPENT AUDITOR'S REPORT TO THE MEMBERS OF WELLCOME TRUST
FINANCE PLC
Report on the audit of the financial statements
1. Opinion
In our opinion the financial statements of Wellcome Trust
Finance plc (the 'company'):
-- give a true and fair view of the state of the company's
affairs as at 30 September 2022 and of its profit for the year then
ended;
-- have been properly prepared in accordance with United Kingdom
Generally Accepted Accounting Practice, including Financial
Reporting Standard 102 "The Financial Reporting Standard applicable
in the UK and Republic of Ireland"; and
-- have been prepared in accordance with the requirements of the Companies Act 2006.
We have audited the financial statements which comprise:
-- the statement of income and retained earnings;
-- the statement of financial position; and
-- the related notes 1 to 17.
The financial reporting framework that has been applied in their
preparation is applicable law and United Kingdom Accounting
Standards, including Financial Reporting Standard 102 "The
Financial Reporting Standard applicable in the UK and Republic of
Ireland" (United Kingdom Generally Accepted Accounting
Practice).
2. Basis for opinion
We conducted our audit in accordance with International
Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our
responsibilities under those standards are further described in the
auditor's responsibilities for the audit of the financial
statements section of our report.
We are independent of the company in accordance with the ethical
requirements that are relevant to our audit of the financial
statements in the UK, including the Financial Reporting Council's
(the 'FRC's') Ethical Standard as applied to listed public interest
entities, and we have fulfilled our other ethical responsibilities
in accordance with these requirements. We confirm that we have not
provided any non-audit services prohibited by the FRC's Ethical
Standard to the company.
We believe that the audit evidence we have obtained is
sufficient and appropriate to provide a basis for our opinion.
3. Summary of our audit approach
Key audit matters The key audit matters that we identified in the current
year were:
* The amortisation of bond liabilities;
* The collectability of intercompany loans.
Within this report, the key audit matters are identified
as follows: -- Similar level of risk
------------------- -----------------------------------------------------------
Materiality The materiality that we used for the financial statements
was GBP13.73m (2021: GBP13.73m) which was determined
on the basis of 2% of total assets (2021: 2% of total
assets)
------------------- -----------------------------------------------------------
Scoping Audit work to respond to the risks of material misstatement
was performed directly by the audit engagement team.
------------------- -----------------------------------------------------------
Significant changes There are no significant changes in our approach.
in our approach
------------------- -----------------------------------------------------------
4. Conclusions relating to going concern
In auditing the financial statements, we have concluded that the
directors' use of the going concern basis of accounting in the
preparation of the financial statements is appropriate.
Our evaluation of the directors' assessment of the company's
ability to continue to adopt the going concern basis of accounting
included the following:
-- We evaluated management's going concern assessment by
reference to the company's current year performance and year-end
position;
-- We assessed the accuracy of management's forecasts by comparing to actual results;
-- We performed a subsequent events review up until the date of
this audit report to assess whether any events have been identified
that are relevant to company's going concern assessment;
-- Assessing the appropriateness of the going concern disclosures in the financial statements.
Based on the work we have performed, we have not identified any
material uncertainties relating to events or conditions that,
individually or collectively, may cast significant doubt on the
company's ability to continue as a going concern for a period of at
least twelve months from when the financial statements are
authorised for issue.
Our responsibilities and the responsibilities of the directors
with respect to going concern are described in the relevant
sections of this report.
5. Key audit matters
Key audit matters are those matters that, in our professional
judgement, were of most significance in our audit of the financial
statements of the current period and include the most significant
assessed risks of material misstatement (whether or not due to
fraud) that we identified. These matters included those which had
the greatest effect on: the overall audit strategy, the allocation
of resources in the audit; and directing the efforts of the
engagement team.
These matters were addressed in the context of our audit of the
financial statements as a whole, and in forming our opinion
thereon, and we do not provide a separate opinion on these
matters.
5.1. Amortisation of bond liabilities
Key audit matter The company has external debt (bonds listed on the
description London Stock Exchange) of GBP550m (2021: GBP550m)
as at 30 September 2022, which is repayable on 24
July 2036 at an interest rate of 4.625% per annum.
These bonds are highly material to the company as
they account for 99.7% of total liabilities of the
company (2021: 99.7%).
The bond liabilities are stated at amortised cost
using the effective interest method and requires
the calculation of the effective interest rate for
their measurement on the balance sheet as at 30 September
2022. This is performed in an amortisation schedule
prepared by management. This calculation has a material
impact on the carrying value of the bond liabilities.
Amortisation of bond liabilities has been identified
as the Key Audit Matter, as this had the largest
impact on the overall audit strategy, the allocation
of resources in the audit and directing the efforts
of the engagement team.
Bond liabilities are disclosed in note 9, as well
as the accounting policies in note 1.
----------------------- ------------------------------------------------------------------
How the scope With regards to the bond liabilities, we:
of our audit responded * obtained the original bond prospectuses to assess
to the key audit whether the terms of the bonds agree to the inputs
matter used by management to calculate the effective
interest rate;
* recalculated the period to period effective interest
and the carried forward balance of the bond
liabilities until maturity;
* assessed the disclosures in the financial statements
relating to bond liabilities as at 30 September 2022.
----------------------- ------------------------------------------------------------------
Key observations As a result of our procedures, we concluded that
the bond liabilities were appropriately stated and
their related disclosures are appropriately reported.
----------------------- ------------------------------------------------------------------
5.2. Collectability of intercompany loans
Key audit matter The company has Loans to Group undertakings relating
description to intercompany loans totalling GBP676m (2021: GBP676m)
due from its Parent, The Wellcome Trust.
These intercompany loans are highly material to the
company as they account 98.5% of total assets of
the company (2021: 98.5%).
The ability of the company to repay the external
debt when it matures and pay the interest to the
bond holders is dependent on the future financial
performance of the Parent and their ability to repay
the intercompany loans to the company. The basis
for this collectability relies on accurate assumptions
in the future forecasts of the Parent and a liquidity
position which does not indicate the need for impairment.
Collectability of intercompany loans has been identified
as the Key Audit Matter, as this had the largest
impact on the overall audit strategy, the allocation
of resources in the audit and directing the efforts
of the engagement team.
Loans to group undertakings are disclosed in note
8, as well as the accounting policies in note 1.
----------------------- ------------------------------------------------------------------
How the scope With regards to the collectability of the loans given
of our audit responded to the Parent, we:
to the key audit * performed a credit risk analysis by assessing the
matter current net asset and liquidity position of the
Parent;
* obtained the cash flow forecast of the Parent and
assessed whether the assumptions in the forecast were
reasonable;
* assessed whether the cash flow forecast and the
liquidity position of the Parent suggested any
indicators of impairment;
* assessed the disclosures in the financial statements
relating to intercompany loans as at 30 September
2022 .
----------------------- ------------------------------------------------------------------
Key observations As a result of our procedures, we concluded that
the intercompany loans were appropriately stated
and their related disclosures are appropriately reported.
----------------------- ------------------------------------------------------------------
6. Our application of materiality
6.1. Materiality
We define materiality as the magnitude of misstatement in the
financial statements that makes it probable that the economic
decisions of a reasonably knowledgeable person would be changed or
influenced. We use materiality both in planning the scope of our
audit work and in evaluating the results of our work.
Based on our professional judgement, we determined materiality
for the financial statements as a whole as follows:
Financial statements
----------------------------------- ---------------------------------------------------------------------------------
Materiality GBP13.73m (2021: GBP13.73m)
----------------------------------- ---------------------------------------------------------------------------------
Basis for determining materiality 2% of total assets (2021: 2% of total assets)
----------------------------------- ---------------------------------------------------------------------------------
Rationale for the benchmark applied Total assets is considered as an appropriate benchmark, as the principal activity
of the entity
is to issue bonds on the London Stock Exchange to provide financing to the
Wellcome Trust
Group, and therefore it is the key area of interest for the users of the
financial statements.
----------------------------------- ---------------------------------------------------------------------------------
6.2. Performance materiality
We set performance materiality at a level lower than materiality
to reduce the probability that, in aggregate, uncorrected and
undetected misstatements exceed the materiality for the financial
statements as a whole. Performance materiality was set at 70% of
materiality for the 2022 audit (2021: 70%).
In determining performance materiality, we considered the
following factors:
-- our risk assessment, including our assessment of the overall control environment; and
-- our past experience of the audit, which has indicated a low
number of corrected and uncorrected misstatements identified in
prior periods.
6.3. Error reporting threshold
We agreed with the Audit and Risk Committee of the Wellcome
Trust, which oversees the group entities, that we would report to
them all audit differences in excess of GBP686k (2021: GBP686k), as
well as differences below that threshold that, in our view,
warranted reporting on qualitative grounds. We also report to the
Audit and Risk Committee on disclosure matters that we identified
when assessing the overall presentation of the financial
statements.
7. An overview of the scope of our audit
7.1. Scoping
Our audit was scoped by obtaining an understanding of the entity
and its environment, including internal control, and assessing the
risks of material misstatement. The audit work to respond to the
risks of material misstatement was performed directly by the audit
engagement team .
8. Other information
The other information comprises the information included in the
annual report, other than the financial statements and our
auditor's report thereon. The directors are responsible for the
other information contained within the annual report.
Our opinion on the financial statements does not cover the other
information and, except to the extent otherwise explicitly stated
in our report, we do not express any form of assurance conclusion
thereon.
Our responsibility is to read the other information and, in
doing so, consider whether the other information is materially
inconsistent with the financial statements or our knowledge
obtained in the course of the audit, or otherwise appears to be
materially misstated.
If we identify such material inconsistencies or apparent
material misstatements, we are required to determine whether this
gives rise to a material misstatement in the financial statements
themselves. If, based on the work we have performed, we conclude
that there is a material misstatement of this other information, we
are required to report that fact.
We have nothing to report in this regard.
9. Responsibilities of directors
As explained more fully in the directors' responsibilities
statement, the directors are responsible for the preparation of the
financial statements and for being satisfied that they give a true
and fair view, and for such internal control as the directors
determine is necessary to enable the preparation of financial
statements that are free from material misstatement, whether due to
fraud or error.
In preparing the financial statements, the directors are
responsible for assessing the company's ability to continue as a
going concern, disclosing as applicable, matters related to going
concern and using the going concern basis of accounting unless the
directors either intend to liquidate the company or to cease
operations, or have no realistic alternative but to do so.
10. Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether
the financial statements as a whole are free from material
misstatement, whether due to fraud or error, and to issue an
auditor's report that includes our opinion. Reasonable assurance is
a high level of assurance, but is not a guarantee that an audit
conducted in accordance with ISAs (UK) will always detect a
material misstatement when it exists. Misstatements can arise from
fraud or error and are considered material if, individually or in
the aggregate, they could reasonably be expected to influence the
economic decisions of users taken on the basis of these financial
statements.
A further description of our responsibilities for the audit of
the financial statements is located on the FRC's website at:
www.frc.org.uk/auditorsresponsibilities . This description forms
part of our auditor's report.
11. Extent to which the audit was considered capable of
detecting irregularities, including fraud
Irregularities, including fraud, are instances of non-compliance
with laws and regulations. We design procedures in line with our
responsibilities, outlined above, to detect material misstatements
in respect of irregularities, including fraud. The extent to which
our procedures are capable of detecting irregularities, including
fraud is detailed below.
11.1. Identifying and assessing potential risks related to irregularities
In identifying and assessing risks of material misstatement in
respect of irregularities, including fraud and non-compliance with
laws and regulations, we considered the following:
-- the nature of the industry and sector, control environment and business performance;
-- results of our enquiries of management and the group's Audit
and Risk Committee, about their own identification and assessment
of the risks of irregularities;
-- any matters we identified having obtained and reviewed the
company's documentation of their policies and procedures relating
to:
o identifying, evaluating and complying with laws and
regulations and whether they were aware of any instances of
non-compliance;
o detecting and responding to the risks of fraud and whether
they have knowledge of any actual, suspected or alleged fraud;
o the internal controls established to mitigate risks of fraud
or non-compliance with laws and regulations;
-- the matters discussed among the audit engagement team and
relevant internal specialists, including IT specialists, regarding
how and where fraud might occur in the financial statements and any
potential indicators of fraud.
As a result of these procedures, we considered the opportunities
and incentives that may exist within the organisation for fraud. In
common with all audits under ISAs (UK), we are required to perform
specific procedures to respond to the risk of management
override.
We also obtained an understanding of the legal and regulatory
framework that the company operates in, focusing on provisions of
those laws and regulations that had a direct effect on the
determination of material amounts and disclosures in the financial
statements. The key laws and regulations we considered in this
context included the UK Companies Act and Listing Rules for the
company's listed bonds.
In addition, we considered provisions of other laws and
regulations that do not have a direct effect on the financial
statements but compliance with which may be fundamental to the
company's ability to operate or to avoid a material penalty. These
included the regulatory requirements of the Charities Act 2011, as
the profit of the Company for the year is paid under Gift Aid to
the Parent entity, Wellcome Trust, a registered charity.
11.2. Audit response to risks identified
As a result of performing the above, we did not identify any key
audit matters related to the potential risk of fraud or
non-compliance with laws and regulations.
Our procedures to respond to risks identified included the
following:
-- reviewing the financial statement disclosures and testing to
supporting documentation to assess compliance with provisions of
relevant laws and regulations described as having a direct effect
on the financial statements;
-- enquiring of management, and the Audit and Risk Committee
concerning actual and potential litigation and claims;
-- performing analytical procedures to identify any unusual or
unexpected relationships that may indicate risks of material
misstatement due to fraud;
-- reading minutes of meetings of those charged with governance
and reviewing correspondence with HMRC; and
-- in addressing the risk of fraud through management override
of controls, testing the appropriateness of journal entries and
other adjustments; assessing whether the judgements made in making
accounting estimates are indicative of a potential bias; and
evaluating the business rationale of any significant transactions
that are unusual or outside the normal course of business.
We also communicated relevant identified laws and regulations
and potential fraud risks to all engagement team members, including
internal specialists, and remained alert to any indications of
fraud or non-compliance with laws and regulations throughout the
audit.
Report on other legal and regulatory requirements
12. Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of
the audit:
-- the information given in the Strategic report and the
Directors' report for the financial year for which the financial
statements are prepared is consistent with the financial
statements; and
-- the Strategic report and the Directors' report have been
prepared in accordance with applicable legal requirements.
In the light of the knowledge and understanding of the company
and its environment obtained in the course of the audit, we have
not identified any material misstatements in the strategic report
or the directors' report.
13. Matters on which we are required to report by exception
13.1. Adequacy of explanations received and accounting records
Under the Companies Act 2006 we are required to report to you
if, in our opinion:
-- we have not received all the information and explanations we require for our audit; or
-- adequate accounting records have not been kept, or returns
adequate for our audit have not been received from branches not
visited by us; or
-- the financial statements are not in agreement with the accounting records and returns.
We have nothing to report in respect of these matters.
13.2. Directors' remuneration
Under the Companies Act 2006 we are also required to report if
in our opinion certain disclosures of directors' remuneration have
not been made.
We have nothing to report in respect of this matter.
14. Other matters which we are required to address
14.1. Auditor tenure
Following the recommendation of the Audit and Risk Committee we
were appointed by the Company at its annual general meeting on 14
December 2015 to audit the financial statements of the Company for
the period ending 30 September 2016 and subsequent financial
periods.
The period of total uninterrupted engagement including previous
renewals and reappointments of the firm is 7 years, covering the
years from our appointment through to the period ending 30
September 2022.
14.2. Consistency of the audit report with the additional report
to the audit and risk committee
Our audit opinion is consistent with the additional report to
the Audit and Risk Committee we are required to provide in
accordance with ISAs (UK).
15. Use of our report
This report is made solely to the company's members, as a body,
in accordance with Chapter 3 of Part 16 of the Companies Act 2006.
Our audit work has been undertaken so that we might state to the
company's members those matters we are required to state to them in
an auditor's report and for no other purpose. To the fullest extent
permitted by law, we do not accept or assume responsibility to
anyone other than the company and the company's members as a body,
for our audit work, for this report, or for the opinions we have
formed.
Jessica Hodges , ACA (Senior statutory auditor)
For and on behalf of Deloitte LLP
Statutory Auditor
London, United Kingdom
9 January 2023
Wellcome Trust Finance plc
Statement of Income and Retained Earnings
For the year ended 30 September 2022
Year ended Year ended
30 September 30 September
Note 2022 2021
GBP GBP
------------------------------------ ----- ------------- -------------
Income 3 29,072,237 38,067,314
Operating income 29,072,237 38,067,314
Cost of sales 4 (25,772,755) (34,666,669)
Administrative expenses 5 (47,908) 15,282
Operating profit 3,251,574 3,415,927
Taxation - -
Profit after taxation 3,251,574 3,415,927
Charitable donation - relating
to current year (3,251,574) (3,415,927)
Retained results for the financial
year - -
------------------------------------ ----- ------------- -------------
Opening shareholder's funds 137,500,000 137,500,000
Retained earnings brought forward - -
Retained profit/(loss) for the
year - -
Dividends declared and paid or
payable during the year - -
Retained earnings carried forward - -
Closing shareholder's funds 137,500,000 137,500,000
------------------------------------ ----- ------------- -------------
All results are derived from continuing activities.
The Company has no gains or losses other than the results for
the financial year as set out above, and therefore no separate
Statement of comprehensive income or Statement of changes in equity
have been presented.
The notes form part of these Financial Statements.
Wellcome Trust Finance plc
Statement of Financial Position
As at 30 September 2022
As at As at
30 September 30 September
Note 2022 2021
GBP GBP
--------------------------------------- ----- -------------- --------------
Non current assets
Loans to Group undertakings 9 676,000,000 676,000,000
Current assets
Amounts owed by Parent undertaking 5,145,081 4,834,474
Accrued interest on loans 5,415,548 5,415,548
Prepayments 9,240 9,000
Cash at bank and in hand 1,146 -
10,571,015 10,259,022
Total assets 686,571,015 686,259,022
--------------------------------------- ----- -------------- --------------
Creditors: amounts falling due
within one year 10 (6,094,306) (6,117,569)
--------------------------------------- ----- -------------- --------------
Net current assets 4,476,709 4,141,453
---------------------------------------
Total assets less current liabilities 680,476,709 680,141,453
--------------------------------------- ----- -------------- --------------
Creditors: amounts falling due
after more than one year 10 (542,976,709) (542,641,453)
Net assets 137,500,000 137,500,000
--------------------------------------- ----- -------------- --------------
Capital and reserves
Called up share capital 12 137,500,000 137,500,000
Retained earnings - -
Total shareholders' funds 11 137,500,000 137,500,000
--------------------------------------- ----- -------------- --------------
The Company has no changes in equity during the year as set out
above and therefore no separate statement of changes in equity has
been presented.
The Financial Statements were approved by the Board of Directors
and authorised for issue on 9 January 2023 and signed on its behalf
by:
Karen Chadwick
Director
9 January 2023
Wellcome Trust Finance Plc
Company Number 5857955
Wellcome Trust Finance plc
Notes to the Financial Statements
For the year ended 30 September 2022
1. ACCOUNTING POLICIES
The Financial Statements are prepared in accordance with
applicable United Kingdom law and United Kingdom accounting
standards. The accounting policies which have been adopted
consistently in the current and prior year are described below.
(a) Statement of compliance
The Company, a public limited company, is incorporated in
England and Wales, United Kingdom under the Companies Act. The
address of the registered office is given in the Administrative
Details section. The nature of the Company's operations and its
principal activities are set out in the Strategic Report.
The Company is a wholly owned subsidiary undertaking of the
Wellcome Trust through its corporate trustee, The Wellcome Trust
Limited, and is included in the Consolidated Financial Statements
of the Wellcome Trust, which are publicly available.
The Financial Statements have been prepared on a going concern
basis as well as in accordance with applicable UK accounting
standards (UK Generally Accepted Accounting Practice), including
Financial Reporting Standard 102 the Financial Reporting Standard
applicable in the United Kingdom and the Republic of Ireland ("FRS
102"). Refer to the Directors' report for more information.
The functional and presentational currency of the Company is
pounds Sterling. Most of transactions undertaken by the Company are
denominated in pounds Sterling.
The Company meets the definition of a qualifying entity under
FRS 102 and has therefore taken advantage of the disclosure
exemptions available to it. Exemptions have been taken in relation
to financial instruments, the presentation of a Statement of Cash
Flows and the Related Party disclosures. The equivalent disclosures
relating to the exemptions have been included in the Consolidated
Financial Statements of the Wellcome Trust at
wellcome.org/news-and-reports/reports .
(b) Summary of significant accounting policies
The principal accounting policies applied in the preparation of
these Financial Statements are set out below. These policies have
been consistently applied to all years presented, unless otherwise
stated.
Basis of preparation
The Financial Statements have been prepared under the historical
cost convention. The preparation of Financial Statements in
conformity with FRS 102 requires the use of certain significant
accounting estimates. It also requires management to exercise its
judgement in the process of applying the Company's accounting
policies. The areas involving more judgement or complexity, or
areas where assumptions and estimates are significant to the
Financial Statements are disclosed in note 2.
(i) Income
Income is interest derived from loans to Wellcome Trust. Income
is calculated using the effective interest rate method and is
recognised on an accruals basis. Interest is earned on amounts due
from the Parent undertaking which are repayable on demand. Interest
is charged at average money market rates quoted by HSBC UK Bank
plc.
(ii) Cost of sales
Expenditure is the effective interest on the Bond liabilities
(as described in Bond Liabilities section below) and is recognised
on an accruals basis and recognised in the statement of income and
retained earnings.
(iii) Gift Aid
The amount of Gift Aid donation recognised for each period is
equal to the estimated taxable profits of the Company for that
period at the time of the approval of the Financial Statements.
Gift Aid donation payments made within nine months after the
balance sheet date are equal to the estimated taxable profits of
the Company for the period at the time of payment less any interim
donations made in the year. Any difference between the Gift Aid
donation accrued and Gift Aid donations paid is recognised at the
time of payment.
(iv) Taxation
Although subject to taxation, the Company does not pay UK
Corporation Tax because its policy is to donate taxable profits as
Gift Aid to the Wellcome Trust. Subject to the above, current tax,
including UK corporation tax and foreign tax, is provided at
amounts expected to be paid (or recovered) using the tax rates and
laws that have been enacted or substantively enacted by the balance
sheet date.
(v) Financial assets and liabilities
The Company has chosen to adopt Sections 11 and 12 of FRS 102 in
respect of financial instruments. Financial assets and financial
liabilities are recognised when the Group becomes a party to the
contractual provisions of the instrument.
Financial liabilities and equity instruments are classified
according to the substance of the contractual arrangements entered
into. All financial assets and liabilities are initially measured
at transaction price (including transaction costs), and
subsequently at amortised cost.
Financial assets which qualify as basic financial instruments as
laid out in FRS 102 paragraph 11.8, including trade and other
receivables and cash and bank balances, are subsequently valued at
amortised cost and assessed for impairment at the end of each
reporting period. Financial assets and liabilities are only offset
in the Statement of Financial Position when, and only when, a
legally enforceable right exists to set off the recognised amounts
and the Group intends either to settle on a net basis, or to
realise the asset and settle the liability simultaneously.
Financial assets are derecognised when and only when (a) the
contractual rights to the cash flows from the financial asset
expire or are settled, (b) the Company transfers to another party
substantially all of the risks and rewards of ownership of the
financial asset, or (c) the Company, despite having retained some,
but not all, significant risks and rewards of ownership, has
transferred control of the asset to another party .
Financial liabilities are derecognised only when the obligation
specified in the contract is discharged, cancelled or expires.
Loans to Parent undertakings
The loans are not quoted in an active market. The loans were
recognised initially at fair value and after initial recognition
are measured at amortised cost using the effective interest
method.
Bond Liabilities
The initial measurement of the liability is equal to the
proceeds of issue less all transaction costs directly attributable
to the issue for each Bond. After initial recognition the liability
is measured at amortised cost using the effective interest method.
The Company is not required to, and therefore does not, recognise
any adjustment to fair value in the Statement of Financial Position
and Statement of Income and Retained Earnings.
2. SIGNIFICANT ACCOUNTING JUDGEMENTS AND KEY SOURCES OF
ESTIMATION UNCERTAINTY
Estimates and judgements are continually evaluated and are based
on historical experience and other factors, including expectations
of future events that are believed to be reasonable under the
circumstances.
Accounting judgements
The Company has made no significant accounting judgements in the
application of the Company's accounting policies that have a
significant risk of causing a material adjustment to the carrying
amounts of assets and liabilities within the next financial
year.
Significant accounting estimates and assumptions
The Company has made no significant accounting estimates and
assumptions in the application of the Company's accounting policies
that have a significant risk of causing a material adjustment to
the carrying amounts of assets and liabilities within the next
financial year.
3. TURNOVER
2022 2021
GBP GBP
Interest receivable on loans to Parent
undertaking 29,068,750 38,067,312
Interest receivable on
cash deposits 3,487 2
29,072,237 38,067,314
---------------------------------------- ----------- -----------
Interest receivable on loans to Parent undertakings in the UK
(see note 9) is the effective interest on:
-- Loan A to Wellcome Trust at a fixed rate of 4.75%;
-- Loan C to Wellcome Trust at fixed rate of 4.00%; and
-- Loan D to Wellcome Trust at fixed rate of 4.125%.
All income is derived from the United Kingdom.
4. COST OF SALES
2022 2021
GBP GBP
Interest payable on bond liabilities 25,772,755 34,666,669
25,772,755 34,666,669
-------------------------------------- ----------- -----------
5. ADMINISTRATIVE EXPENSES
2022 2021
GBP GBP
Auditor's remuneration 27,744 24,912
Rating agency
fees 17,520 (44,565)
Tax compliance 2,554 1,886
Other 90 2,485
47,908 (15,282)
------------------------ ------- ---------
Auditor's remuneration is solely in relation to the statutory
audit of the Financial Statements. 2021 rating agency fees include
the release of a legacy fee accrual of GBP69,948.
6. EMPLOYEE INFORMATION
The Company has no employees (2021: nil). Employees of The
Wellcome Trust Limited (acting as trustee of the Wellcome Trust)
undertake the administration of the Company at no incremental cost
to the Wellcome Trust.
7. REMUNERATION OF DIRECTORS
The Directors of the Company received no remuneration from the
Company for their services. There were no Directors for whom
retirement benefits provided by the Company are accruing under a
money purchase or defined benefit scheme. The Company does not
issue share options or offer any long-term incentive schemes, so
there were no Directors who exercised share options during the year
or became entitled to shares under a long-term incentive
scheme.
8. TAX ON RESULT
The profits of the Company for the year will be paid under Gift
Aid to the Wellcome Trust, a charity registered in England under
the UK Charities Act 2011 (registered charity number 210183). There
is no difference between retained profit/(loss) and taxable
profits, so there is no provision required for deferred tax.
2022 2021
GBP GBP
Profit before tax 3,251,574 3,415,927
Current tax charge
for the year:
Tax on profit on ordinary activities
at 617,799 649,026
standard corporation tax rate of 19% (2021:
19%)
Gift aid donation to Wellcome Trust (617,799) (649,026)
Total current tax - -
---------------------------------------------- ---------- ----------
The standard rate of corporation tax applied to taxable profit
is 19% per cent (2021: 19%). The corporation tax rate is due to
increase to 25% (effective 1 April 2023) following the substantive
enactment of Finance Act 2021. Subject to recognition criteria, all
deferred tax assets and liabilities are recognised at a rate of
25%.
As per the tax note above, Wellcome Trust Finance plc generated
tax profits of GBP3,251,574 in the year. Taxable profits have been
extinguished to GBPnil due to qualifying charitable donations
("Gift Aid") paid to Wellcome Trust.
9. LOANS TO PARENT UNDERTAKING
Amortised Amortised
cost cost
Interest
Principal rate per Loan anniversary
amount annum date 2022 2021
GBP % GBP GBP
Non Current Assets
Loan
A 245,500,000 4.750 25 July 245,500,000 245,500,000
Loan
C 280,500,000 4.000 25 July 280,500,000 280,500,000
Loan
D 150,000,000 4.125 25 July 150,000,000 150,000,000
676,000,000 676,000,000 676,000,000
------- ------------- ---------- ----------------- ------------ ------------
Loans to Parent undertakings are loans (the "Loans") to Wellcome
Trust (Loan A, Loan C and Loan D. The principal under Loan A is
repayable on demand by the Company. The principal under Loan C and
Loan D is repayable on agreement between the Company and Wellcome
Trust. The Loans have an agreed repayment date on 25 July 2036
(Loan A, Loan C and Loan D). Each Loan has a fixed redemption value
equal to the principal amount and a fixed interest rate.
10. CREDITORS
2022 2021
GBP GBP
Accruals and deferred
income 2,540 3,258
Gift Aid due to the Wellcome
Trust 1,352,725 1,375,270
Bond liabilities 4,739,041 4,739,041
Total creditors: amounts falling
due within one year 6,094,306 6,117,569
--------------------------------------- ------------ ------------
Bond liabilities 542,976,709 542,641,453
Falling due after five
years 542,976,709 542,641,453
-------------------------------------- ------------ ------------
Total creditors: amounts falling
due after one year 542,976,709 542,641,453
--------------------------------------- ------------ ------------
The Bond liabilities are stated at the amortised cost using the
effective interest method for the GBP550 million 4.625% Guaranteed
Bonds due July 2036 ("GBP550 million Bonds"), issued by the Company
on 25 July 2006. The Bond liabilities falling due within one year
are the unpaid coupon interest accrued for the year to 30 September
2022. The interest payment to the Bond holders is at a fixed rate
of 4.625% per annum (GBP550 million Bonds) and is paid in arrears
on 25 July each year until repayment of the Bond principal. The
bond repayment and amounts receivable from group companies are
aligned in timing for liquidity management. Effective interest on
bond liabilities is shown as Cost of Sales in the Statement of
Income and Retained Earnings.
The obligation of the Company on the Bonds is governed by a
Trust Deed dated 25 July 2006 (GBP550 million Bonds) between the
Company, The Wellcome Trust Limited, as trustee of the Wellcome
Trust, and Citicorp Trustee Company Limited, as the trustee for the
holders of the Bonds (the "Trust Deed"). The payment of all amounts
due in respect of the Bonds is unconditionally and irrevocably
guaranteed pursuant to the terms of a guarantee given by The
Wellcome Trust Limited, as corporate trustee of the Wellcome Trust;
the guarantee is part of the Trust Deed.
11. RECONCILIATION OF MOVEMENTS IN SHAREHOLDER'S FUNDS
Shareholder's
Funds
GBP
As at 30 September 2021 137,500,000
As at 30 September
2022 137,500,000
----------------------------- ------------------------------
12. CALLED UP SHARE CAPITAL
2022 2021
Number GBP GBP
Issued and fully paid
ordinary
shares of GBP1 each 137,500,000 137,500,000 137,500,000
---------------------------- ------------ ------------------------------ ------------------------------
13. RELATED PARTY TRANSACTIONS
The Company has taken advantage of the exemption contained in
FRS 102 Section 33 paragraph 33.1A3 "Related Party Disclosures",
which exempts it from disclosing details of transactions with the
Wellcome Trust and its subsidiary undertakings, as the Company and
its related undertakings with whom it may have transactions are
wholly owned subsidiaries of the Wellcome Trust through its
corporate trustee, The Wellcome Trust Limited. There are no other
related party transactions requiring disclosure.
14. FINANCIAL INSTRUMENTS
The Company's financial instruments comprise the loans to Parent
undertaking and the liability arising from the issue of the Bonds.
The Company's loans are non-derivative financial assets with fixed
payments which are not available for sale. The Bond liability is a
non-derivative financial liability with a fixed redemption value,
fixed interest rate and fixed maturity date. The Company has not
undertaken any trading in financial instruments during the
year.
The financial instruments issued by, or held by, the Company are
Sterling denominated and at fixed interest rates and carry no
foreign exchange risk or interest rate risk.
The key risks relating to the financial instruments held by the
Company are the credit risk and liquidity risk of the counterparty
Wellcome Trust in relation to the loans to Parent undertakings.
These risks are in respect of the Wellcome Trust's ability to meet
the interest and principal payments as they fall due. The total
value exposed to credit risk as at 30 September 2022 is GBP686.6
million (2021: GBP686.2 million), which comprises the value of the
loans to Parent undertakings, amounts owed by the Parent
undertakings, accrued interest on loans and cash at bank and in
hand. The liquidity risk of the Company is mitigated by the exact
matching of the cash flows from the Company's loans to the Parent
undertakings to those arising on the Bond Liabilities.
Credit risk exposure of the Company's loans is reduced by the
Company only advancing loans to entities within the Group. Credit
risk exposure of the Company's remaining financial assets is
reduced by stringent selection procedures for any external
counterparties with which the Company transacts.
15. COMMITMENTS
The Company has no outstanding commitments to make further
investments at 30 September 2022 (2021: GBPnil).
16. ULTIMATE PARENT UNDERTAKING AND CONTROLLING PARTY
The Company is a company limited by shares. Its sole shareholder
is the Wellcome Trust through its corporate trustee, The Wellcome
Trust Limited, whose place of business is Gibbs Building, 215
Euston Road, London, United Kingdom. The Company is considered a
wholly owned subsidiary undertaking of the Wellcome Trust for
accounting purposes and its assets and liabilities have been
consolidated with those of the Wellcome Trust as required by
section 9 of FRS 102.
The ultimate parent undertaking and controlling party of the
Company is the Wellcome Trust, which is the parent undertaking of
the smallest and largest group to consolidate these Financial
Statements.
Copies of the Wellcome Trust Annual Report and Financial
Statements 2022 are available from Wellcome's website (
wellcome.org/news-and-reports/reports ) or from the Company
Secretary.
17. EVENTS AFTER THE END OF THE REPORTING PERIOD
There have been no subsequent events requiring disclosure.
Wellcome Trust Finance plc
Administrative Details
As at 30 September 2022
Directors
Karen Chadwick
Nicholas Moakes
Peter Pereira Gray (resigned on 30 September 2022)
Fabian Thehos
Company Secretary
Christopher Bird
Registered Company Number
5857955
Registered Office
Gibbs Building
215 Euston Road
London
NW1 2BE
Independent Auditor
Deloitte LLP
Statutory Auditor
1 New Street Square
London
EC4A 3HQ
Banker
HSBC Bank plc
31 Holborn Circus
Holborn
London
EC1N 2HR
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
FR NKCBDDBKDPDK
(END) Dow Jones Newswires
January 10, 2023 02:00 ET (07:00 GMT)
Wellcome 4.625% (LSE:57MC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Wellcome 4.625% (LSE:57MC)
Historical Stock Chart
From Dec 2023 to Dec 2024
